HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
UNLABELLED: NAFLD is the most common liver disease worldwide but it is the potential evolution to NASH and eventually to hepatocellular carcinoma (HCC), even in the absence of cirrhosis, that makes NAFLD of such clinical importance. AIM: we aimed to create a mouse model reproducing the pathological spectrum of NAFLD and to investigate the role of possible co-factors in promoting HCC. METHODS: mice were treated with a choline-deficient L-amino-acid-defined-diet (CDAA) or its control (CSAA diet) and subjected to a low-dose i.p. injection of CCl4 or vehicle. Insulin resistance was measured by the euglycemic-hyperinsulinemic clamp method. Steatosis, fibrosis and HCC were evaluated by histological and molecular analysis. RESULTS: CDAA-treated mice showed peripheral insulin resistance at 1 month. At 1-3 months, extensive steatosis and fibrosis were observed in CDAA and CDAA+CCl4 groups. At 6 months, equal increase in steatosis and fibrosis was observed between the two groups, together with the appearance of tumor. At 9 months of treatment, the 100% of CDAA+CCl4 treated mice revealed tumor versus 40% of CDAA mice. Insulin-like Growth Factor-2 (IGF-2) and Osteopontin (SPP-1) were increased in CDAA mice versus CSAA. Furthermore, Immunostaining for p-AKT, p-c-Myc and Glypican-3 revealed increased positivity in the tumors. CONCLUSIONS: the CDAA model promotes the development of HCC from NAFLD-NASH in the presence of insulin resistance but in the absence of cirrhosis. Since this condition is increasingly recognized in humans, our study provides a model that may help understanding mechanisms of carcinogenesis in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Bacterial translocation can be defined as the passage of bacteria, or bacterial products such as LPS, into the portal circulation and happens when the complex regulation of the mechanisms of the gut barrier is lost [276], which has been linked with the occurrence of NAFLD, NASH, hepatic fibrosis, and HCC in several rodent models [227,228,277].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [277]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The severity was assessed by using the NAS scoring system [13].”
MethodManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“Most of these ‘‘cryptogenic’’ HCC might be attributed to Non-Alcoholic Fatty Liver Disease (NAFLD) and the concomitant metabolic syndrome [2,3], nevertheless it is not yet clear what predisposes to the progression of the disease [4].”
BackgroundInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979 · cited 1×
“Indeed, HCC almost always develops on a background of chronic liver injury including chronic hepatitis and cirrhosis, conditions referred as preneoplastic stages [39].”
BackgroundMolecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 5×
“To investigate if CDAA was worsening also hepatic insulin resistance, we have measured the expression of liver enzymes associated with glucose production (G6Pase), gluconeogenesis (PEPCK) and de-novo lipogenesis as SREBP-1c and ChREBP [16,35].”
BackgroundInfluentialFausto, N., Campbell, J. S., & Riehle, K. J. (2006) · Hepatology · doi:10.1002/hep.20969 · Cited by 1,378
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770 · cited 1×
“In human patients with NAFLD/NASH, peripheral insulin resistance is a primary feature of the disease, even in lean subjects that do not present the characteristics of metabolic syndrome [34].”
BackgroundSelf-citationToll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741 · cited 2×
“insulinemic state [24,25].”
BackgroundGall, W. E., Beebe, K., Lawton, K. A., Adam, K.-P., Mitchell, M. W., Nakhle, P. J., Ryals, J. A., Milburn, M. V., Nannipieri, M., Camastra, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010883 · Cited by 698
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666 · cited 1×
“In a majority of Inflammasomes, activation of Caspase-1 requires interaction with the adaptor protein ASC and this leads to increased IL-1b synthesis and secretion, that finally synergizes with TNFa to induce cytotoxicity, HSC activation and maintenance of macrophages in inflammatory state [43].”
BackgroundCalvisi, D. F., Wang, C., Ho, C., Ladu, S., Lee, S. A., Mattu, S., Destefanis, G., Delogu, S., Zimmermann, A., Ericsson, J., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.006 · Cited by 595 · cited 1×
“Furthermore, Immunohistochemical evaluation of p-AKT, p-c-Myc and Glypican-3, that are associated to diagnosis and classification of human HCC, reveals a positive staining also in our mouse model [17–19].”
BackgroundSpencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., & Fodor, A. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.049 · Cited by 593 · cited 1×
“the gut microbiota metabolism of choline as shown in humans [27].”
BackgroundFrom the metabolic syndrome to NAFLD or vice versa?
Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Järvinen, H., & Svegliati-Baroni, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.016 · Cited by 497
Self-citationObesity, inflammation, and liver cancer
Sun, B., & Karin, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.020 · Cited by 496 · cited 1×
“Thus, it is possible that the inflammatory milieu occurring in the damaged liver in our model favors survival of preneoplastic hepatocytes, promotes the generation of a fibrotic substrate and eventually contributes to carcinogenesis [44].”
BackgroundInflammasomes in liver diseases
Szabo, G., & Csak, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.035 · Cited by 495 · cited 1×
“Inflammasomes are intracellular multiprotein complexes expressed in both parenchymal and non-parenchymal cells of the liver that in response to cellular danger signals activate Caspase-1 and release the pro-inflammatory cytokine IL-1b, and their role in NASH development is controversial [42].”
BackgroundKoteish, A., & Diehl, A. M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-12932 · Cited by 445 · cited 1×
“The use of a choline-deficient L-aminoaciddefined diet (CDAA) in rats provided the most interesting results inducing steatohepatitis [7].”
MethodMolecular basis and mechanisms of progression of non-alcoholic steatohepatitis
Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G., & Tiribelli, C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.003 · Cited by 425 · cited 1×
“However, the study of the molecular mechanisms linking steatosis development to chronic liver injury and HCC is hampered by the lack of adequate experimental models that often do not resemble the human situation [22], either are not associated to a significant development of chronic liver injury or lead to a cachectic…”
BackgroundSelf-citationSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Self-citationInflammation and Liver Cancer: New Molecular Links
Berasain, C., Castillo, J., Perugorria, M. J., Latasa, M. U., Prieto, J., & Avila, M. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03704.x · Cited by 390
Ferrannini, E., Natali, A., Camastra, S., Nannipieri, M., Mari, A., Adam, K.-P., Milburn, M. V., Kastenmüller, G., Adamski, J., Tuomi, T., et al. (2013) · Diabetes · doi:10.2337/db12-0707 · Cited by 349
IGF2: Epigenetic regulation and role in development and disease
Chao, W., & D’Amore, P. A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.01.005 · Cited by 336 · cited 1×
“Specifically, both in the CDAA and CDAA+CCl4 groups increased mRNA levels of IGF-2 and SPP-1 genes, respectively involved in angiogenesis and migration/metastasis [48], and decreased mRNA levels of the oncosoppressor gene PTEN were observed at 3 and 9 months [49,50], additionally confirming the neoplastic potential of…”
BackgroundDysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice
De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., et al. (2014) · Hepatology · doi:10.1002/hep.26695 · Cited by 279
Self-citationYang, L., Roh, Y. S., Song, J., Zhang, B., Liu, C., Loomba, R., & Seki, E. (2014) · Hepatology · doi:10.1002/hep.26698 · Cited by 275 · cited 1×
“On the other hand, the reduction in ACOX-1 and CPT1A indicates that CDAA diet reduced hepatic fatty acid oxidation and this could be one of the mechanisms for hepatic triglyceride deposition and for the higher lipid deposition in CDAA+CCl4 treated animals, presumably mediated by TGFb signaling in hepatocytes [12] [37].”
BackgroundKodama, Y., Kisseleva, T., Iwaisako, K., Miura, K., Taura, K., De Minicis, S., Österreicher, C. H., Schnabl, B., Seki, E., & Brenner, D. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.045 · Cited by 195
Pekow, J. R., Bhan, A. K., Zheng, H., & Chung, R. T. (2007) · Cancer · doi:10.1002/cncr.22701 · Cited by 185 · cited 1×
“represent independent risk factors for HCC development [45,46].”
BackgroundGastaldelli, A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70015-8 · Cited by 177 · cited 1×
“Metabolomics data have indicated that reduced concentrations of lysophosphocholine, in particular reduced lyso-PC C18:2, and lyso-PC C16:0, are associated with peripheral insulin resistance [28] and hepatic steatosis [29,30] [31].”
BackgroundSelf-citationNatural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis
Day, C. P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.041 · Cited by 176 · cited 1×
“Most of these ‘‘cryptogenic’’ HCC might be attributed to Non-Alcoholic Fatty Liver Disease (NAFLD) and the concomitant metabolic syndrome [2,3], nevertheless it is not yet clear what predisposes to the progression of the disease [4].”
BackgroundA 360-degree overview of paediatric NAFLD: Recent insights
Nobili, V., Svegliati-Baroni, G., Alisi, A., Miele, L., Valenti, L., & Vajro, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.003 · Cited by 171
Self-citationImpact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats
Nakano, T., Cheng, Y., Lai, C.-Y., Hsu, L., Chang, Y., Deng, J., Huang, Y.-Z., Honda, H., Chen, K., Wang, C., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.028 · Cited by 155 · cited 1×
“insulinemic state [24,25].”
Gastaldelli, A., Toschi, E., Pettiti, M., Frascerra, S., Quiñones-Galvan, A., Sironi, A. M., Natali, A., & Ferrannini, E. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1807 · Cited by 150 · cited 1×
“This is in agreement with the observed reduction in FPG and possibly due to the increase in fasting plasma insulin that is known to suppress both glucose production and gluconeogenesis [36].”
Self-citationPeripheral Disruption of the Grb10 Gene Enhances Insulin Signaling and Sensitivity In Vivo
Wang, L., Balas, B., Christ-Roberts, C. Y., Kim, R. Y., Ramos, F. J., Kikani, C. K., Li, C., Deng, C., Reyna, S., Musi, N., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00679-07 · Cited by 138 · cited 1×
“Here insulin resistance was measured by the euglycemic-hyperinsulinemic clamp, which represents the gold standard for the evaluation of insulin sensitivity [26], and the results were confirmed by finding increased fasting insulin concentrations (Figure 1).”
MethodPage, J. M., & Harrison, S. A. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.007 · Cited by 136 · cited 1×
“Most of these ‘‘cryptogenic’’ HCC might be attributed to Non-Alcoholic Fatty Liver Disease (NAFLD) and the concomitant metabolic syndrome [2,3], nevertheless it is not yet clear what predisposes to the progression of the disease [4].”
BackgroundCirculating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver
Lehmann, R., Franken, H., Dammeier, S., Rosenbaum, L., Kantartzis, K., Peter, A., Zell, A., Adam, P., Li, J., Xu, G., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1760 · Cited by 109 · cited 1×
“Metabolomics data have indicated that reduced concentrations of lysophosphocholine, in particular reduced lyso-PC C18:2, and lyso-PC C16:0, are associated with peripheral insulin resistance [28] and hepatic steatosis [29,30] [31].”
BackgroundSelf-citationPTEN in liver diseases and cancer
Peyrou, M., Bourgoin, L., & Foti, M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i37.4627 · Cited by 96 · cited 1×
“Specifically, both in the CDAA and CDAA+CCl4 groups increased mRNA levels of IGF-2 and SPP-1 genes, respectively involved in angiogenesis and migration/metastasis [48], and decreased mRNA levels of the oncosoppressor gene PTEN were observed at 3 and 9 months [49,50], additionally confirming the neoplastic potential of…”
BackgroundDenda, A., Kitayama, W., Kishida, H., Murata, N., Tsutsumi, M., Tsujiuchi, T., Nakae, D., & Konishi, Y. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01250.x · Cited by 93 · cited 1×
“reported a 100% incidence in preneoplastic foci after 65 weeks of treatment, with no further information on the presence of lesions at earlier time points [47].”
BackgroundPredominant role of gluconeogenesis in the hepatic glycogen repletion of diabetic rats.
Giaccari, A., & Rossetti, L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115583 · Cited by 84 · cited 1×
“After 1 month of treatment, we evaluated peripheral insulin resistance by the euglycemic-hyperinsulinemic clamp method [10].”
MethodSelf-citationGiaccari, A., Morviducci, L., Zorretta, D., Sbraccia, P., Leonetti, F., Caiola, S., Buongiorno, A. M., Bonadonna, R. C., & TAMBURRANO, G. (1995) · Diabetologia · doi:10.1007/bf00400719 · Cited by 83 · cited 1×
“Surgery for the positioning of catheters was performed 3 to 5 days prior to the insulin clamp procedure as previously described [11].”
MethodSelf-citationFrom NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
De Minicis, S., Day, C., & Svegliati-Baroni, G. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319290006 · Cited by 78
Self-citationSvegliati‐Baroni, G., Bugianesi, E., Bouserhal, T., Marini, F., Ridolfi, F., Tarsetti, F., Ancarani, F., Petrelli, E., Peruzzi, E., Cascio, M. L., et al. (2007) · Gut · doi:10.1136/gut.2006.107946 · Cited by 78 · cited 2×
“Moreover, a worse peripheral insulin resistance state has been associated with the presence of fibrosis [8].”
BackgroundSelf-citationPTEN at the crossroad of metabolic diseases and cancer in the liver
Vinciguerra, M., & Foti, M. (2008) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31848-4 · Cited by 63 · cited 1×
“Specifically, both in the CDAA and CDAA+CCl4 groups increased mRNA levels of IGF-2 and SPP-1 genes, respectively involved in angiogenesis and migration/metastasis [48], and decreased mRNA levels of the oncosoppressor gene PTEN were observed at 3 and 9 months [49,50], additionally confirming the neoplastic potential of…”
BackgroundUp-regulation of glypican-3 in human hepatocellular carcinoma.
Suzuki, M., Sugimoto, K., Tanaka, J., Tameda, M., Inagaki, Y., Kusagawa, S., Nojiri, K., Beppu, T., Yoneda, K., Yamamoto, N., et al. (2010) · PubMed · Cited by 55
Minicis, S. D., Candelaresi, C., Agostinelli, L., Taffetani, S., Saccomanno, S., Rychlicki, C., Trozzi, L., Marzioni, M., Benedetti, A., & Svegliati‐Baroni, G. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02860.x · Cited by 53
Self-citationBurgess, A., Vanella, L., Bellner, L., Schwartzman, M. L., & Abraham, N. G. (2011) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2011.10.002 · Cited by 42 · cited 3×
“Furthermore, the Carbohydrate-Responsive Element-Binding Protein (ChREBP), a key element of glucosemediated stimulation of lipogenesis [16] progressively decreased in CDAA-treated animals, independently from CCl4 administration, starting at 1 month (Fig.”
BackgroundSvegliati‐Baroni, G., Faraci, G., Fabris, L., Saccomanno, S., Cadamuro, M., Pierantonelli, I., Trozzi, L., Bugianesi, E., Guido, M., Strazzabosco, M., et al. (2010) · Gut · doi:10.1136/gut.2010.219741 · Cited by 34
Self-citationSvegliati‐Baroni, G., Ghiselli, R., Marzioni, M., Alvaro, D., Mocchegiani, F., Saccomanno, S., Sisti, V., Ugili, L., Orlando, F., Alpini, G. D., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.032 · Cited by 24 · cited 1×
“Quantitative morphometry was performed as previously described [14,15].”
MethodSelf-citation1251 DYSBIOSIS CONTRIBUTES TO FIBROGENESIS IN THE COURSE OF LIVER DAMAGE
Minicis, S. D., Rychlicki, C., Agostinelli, L. J., Saccomanno, S., Trozzi, L., Marzioni, M., Benedetti, A., & Svegliati‐Baroni, G. (2013) · Journal of Hepatology · doi:10.1016/s0168-8278(13)61252-0 · Cited by 3
Self-citationFerrannini, E., Natali, A., Camastra, S., et al. (2012) · CINECA IRIS Institutial research information system (University of Pisa) · Cited by 3
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Accelerated by insulin resistance accumulating metabolites of saturated fatty acids cause lipotoxicity that damages hepatocytes and results in oxidative stress [214, 215].”
BackgroundNonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
“Also, mice fed a CDAA diet develop peripheral IR after 1 month of treatment, and a progressive increase in body weight (102).”
BackgroundTsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
“Adipose tissue insulin resistance is likely to play a significant role since it is related to increased liver damage [124,131].”
BackgroundSelf-citationPierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Self-citation
Metadata
- Authors
- De Minicis, S., Agostinelli, L., Rychlicki, C., Sorice, G. P., Saccomanno, S., Candelaresi, C., Giaccari, A., Trozzi, L., Pierantonelli, I., Mingarelli, E., Marzioni, M., Muscogiuri, G., Gaggini, M., Benedetti, A., Gastaldelli, A., Guido, M., & Svegliati-Baroni, G.
- Affiliations
- Marche Polytechnic University (IT)
- Università Cattolica del Sacro Cuore (IT)
- Istituto di Fisiologia Clinica (IT)
- University of Padua (IT)
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-22
- Volume
- 9
- Issue
- 5
- Pages
- e97136
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4031080
- OpenAlex
- W2086542332
- Cited by
- 97
- References
- 53
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 10 · 2020: 16 · 2019: 12 · 2018: 12 · 2017: 7 · 2016: 6 · 2015: 5 · 2014: 1
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Funders
- European Commission (241762)
- Ministero della Salute (GR-2010, GR-2010-2306996)
- Ministero dell’Istruzione, dell’Università e della Ricerca (2007–2013, PRIN 2009, FIRB2010, 2009X84L84_003)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, peripheral insulin resistance, choline-deficient L-amino acid-defined diet, carbon tetrachloride, liver fibrosis, hepatic steatosis, insulin-like growth factor II, osteopontin, Akt phosphorylation, c-Myc, glypican-3, hepatocarcinogenesis, mouse model
- MeSH terms
- Age Factors, Animals, Choline Deficiency, Disease Models, Animal, Food, Formulated, Carcinoma, Hepatocellular, Insulin Resistance, Insulin-Like Growth Factor II, Liver Neoplasms, Proto-Oncogene Proteins c-myc, Mice, Osteopontin, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.